FluBlok®: Gaining Regulatory Approval Following Phase 3 Studies

flublok, r&d, download

FluBlok® is one of many vaccines in development in the fight against flu.

Dan Adams, Executive Chairman, Global Head of Business Development, Protein Sciences Corporation presented a case study at the World Influenza Congress in 2011, discussing his company's product FluBlok®: Gaining Regulatory Approval Following Phase 3 Studies. His presentation was structured around the following points:

•    Company overview: business segments
•    Proprietary insect cell platform technology
•    Lead vaccines: FluBlok® and PanBlok ®
•    Quality by design
•    Challenges to approval
•    Take-home lessons

Why not download the full presentation and find out more about FluBlok®!

Snapshot of presentation:

  • Founded in 1983, privately held vaccine company, Meriden, CT
  • Patented platform technology using the baculovirus and insect cell system (BEVS)
    • Adopters include: BI Vetmedica; Astellas; Wako (Takeda); Dendreon; Diamyd; BARDA; NIH
    • Patented high density manufacturing technology – insect & CHO cells
  • Recombinant platform: novel human & veterinary prophylactic & therapeutic vaccines
  • Lead influenza vaccine (FluBlok) on track for FDA approval early in 2012
  • Grown from 40 to >90 employees in past 18 months
  • Profitable, cash flow positive business
    • $147 million BARDA contract funds work on FluBlok and PanBlok
    • Japanese contracts & licensees generate significant current cash & royalties in 2012-2024
  • Simplified balance sheet in 2010: debt free; only common stock
  • Avoided VCs and "death by a thousand cuts"
  • Settled all issues related to failed hostile takeover attempt by EBSI

Download the full presentation here!

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Comments 1

Leave a Reply

Your email address will not be published. Required fields are marked *